Cargando…

Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets

High‐risk neuroblastoma (NB) patients with 11q deletion frequently undergo late but consecutive relapse cycles with fatal outcome. To date, no actionable targets to improve current multimodal treatment have been identified. We analyzed immune microenvironment and genetic profiles of high‐risk NB cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coronado, Esther, Yañez, Yania, Vidal, Enrique, Rubio, Luis, Vera‐Sempere, Francisco, Cañada‐Martínez, Antonio José, Panadero, Joaquín, Cañete, Adela, Ladenstein, Ruth, Castel, Victoria, Font de Mora, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858123/ https://www.ncbi.nlm.nih.gov/pubmed/33252831 http://dx.doi.org/10.1002/1878-0261.12868

Ejemplares similares

Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: J Ribelles, Antonio, et al.
Publicado: (2019)

Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor
por: Hämmerle, Barbara, et al.
Publicado: (2013)

TIAM1 variants improve clinical outcome in neuroblastoma
por: Sanmartín, Elena, et al.
Publicado: (2017)

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: Juan Ribelles, Antonio, et al.
Publicado: (2020)

Two independent epigenetic biomarkers predict survival in neuroblastoma
por: Yáñez, Yania, et al.
Publicado: (2015)

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
por: Olivera, Gladys G., et al.
Publicado: (2020)

Retinoblastoma and mosaic 13q deletion: a case report
por: Gargallo, Pablo, et al.
Publicado: (2021)

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion
por: Villamón, Eva, et al.
Publicado: (2013)

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas
por: Juan Ribelles, Antonio, et al.
Publicado: (2021)

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
por: Olivera, Gladys G., et al.
Publicado: (2021)

Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
por: Trinidad, Eva María, et al.
Publicado: (2023)

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
por: Olivera, Gladys, et al.
Publicado: (2019)

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA
por: Trinidad, Eva María, et al.
Publicado: (2023)

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma
por: Burgos-Panadero, Rebeca, et al.
Publicado: (2019)

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study (‖)
por: Morini, Martina, et al.
Publicado: (2019)

Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care
por: Gargallo, Pablo, et al.
Publicado: (2021)

Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration()
por: Berbegall, Ana P., et al.
Publicado: (2014)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma
por: Piqueras, M, et al.
Publicado: (2011)

Intratumoral diversity of telomere length in individual neuroblastoma tumors
por: Pezzolo, Annalisa, et al.
Publicado: (2014)

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
por: De Bernardi, B, et al.
Publicado: (2008)

11q deletion in neuroblastoma: a review of biological and clinical implications
por: Mlakar, Vid, et al.
Publicado: (2017)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Lymph microvascularization as a prognostic indicator in neuroblastoma
por: Tadeo, Irene, et al.
Publicado: (2018)

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
por: Berlanga, Pablo, et al.
Publicado: (2016)

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
por: Jie, H-B, et al.
Publicado: (2013)

Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
por: Zhou, Yan, et al.
Publicado: (2020)

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
por: Ehrlich, Debra, et al.
Publicado: (2014)

Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma
por: Li, Chao, et al.
Publicado: (2022)

Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk
por: Chang, Xiao, et al.
Publicado: (2017)

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
por: Monferrer, Ezequiel, et al.
Publicado: (2019)

Author Correction: Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
por: Zhou, Yan, et al.
Publicado: (2021)

The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
por: Veiga-Canuto, Diana, et al.
Publicado: (2023)

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
por: Matthay, K K, et al.
Publicado: (2010)

Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses
por: Abbasi, M. Reza, et al.
Publicado: (2014)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q7sq090nm4hinnigcg4q18f92g